Trials / Completed
CompletedNCT00109330
A Combined Tdap Vaccine Used As A Booster Compared To Licensed Td Vaccine
A Phase III, Observer-blinded Randomised, Multi-centre Clinical Study of the Safety, Immunogenicity and Consistency of Three Manufacturing Lots of GSK Biologicals' Candidate Tdap Vaccine as Compared to a US-licensed Td Vaccine When Given as a Booster Dose to Healthy Adolescents (10-18 Years of Age)
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 4,116 (actual)
- Sponsor
- GlaxoSmithKline · Industry
- Sex
- All
- Age
- 10 Years – 18 Years
- Healthy volunteers
- Accepted
Summary
This study will evaluate the safety and immune response to GlaxoSmithKline Tdap vaccine compared to licensed Td vaccine when used as a booster in healthy adolescents (10-18 years of age).
Detailed description
A combined Tdap (Tetanus, Diphteria, Acellular Pertussis) Vaccine Used as a Booster compared to Licensed Td (Tetanus and Diphteria) vaccine
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | Combined diphtheria, tetanus, acellular pertussis vaccine |
Timeline
- Start date
- 2002-11-01
- Primary completion
- 2004-04-01
- Completion
- 2004-04-01
- First posted
- 2005-04-27
- Last updated
- 2016-09-09
Locations
44 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT00109330. Inclusion in this directory is not an endorsement.